Lv4
422 积分 2023-01-11 加入
The breast cancer drug market
1天前
已完结
Addressing the unmet need in NSCLC progression with advances in second-line therapeutics
5天前
已关闭
Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132
8天前
已关闭
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
9天前
已完结
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
9天前
已完结
Lung cancer statistics, 2023
9天前
已完结
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
20天前
已完结
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer
20天前
已完结
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments
21天前
已完结
The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease and/or pneumonitis: A systematic review and single-arm meta-analysis
23天前
已完结
皖公网安备34019202002308
